InMode Ltd vs Quantumscape Corp — how do they compare? InMode Ltd trades at $14.07 (market cap $809.93M), while Quantumscape Corp trades at $4.54 (market cap $2.82B). The key difference: Quantumscape Corp is far larger — about 3.5× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 29 Days and Quantumscape Corp for 37 Days on average.
| INMD | QS | |
|---|---|---|
Market Cap | $809.93M | $2.82B |
Volume | 365,490 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $16.62 | $18.44 |
52-Week Low | $12.76 | $4.52 |
Typical Hold Time | 29 Days | 37 Days |
Enterprise Value | $313.27M | $2.03B |
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.01, up 0.14% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 earnings of $0.35 per share, beating expectations, and maintains a strong gross profit margin of 76.52%. Recent news includes the launch of Morpheus8 Cool and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The outlook is mixed: valuation metrics like P/E of 11.63 and EV/EBITDA of 4.48 appear attractive, but declining net income and bearish technicals pose risks. Analyst consensus is divided with 45.45% buy ratings, highlighting potential upside from strategic developments against execution challenges.
QuantumScape (QS) trades at $4.52, down 2.8% on the day, reflecting ongoing investor skepticism about the solid-state battery developer's path to commercialization. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamental challenges persist with zero revenue, negative EBITDA of -$358.25M (2025), and consecutive quarterly losses. Recent news highlights commercialization delays and insider selling, though the company continues ramping pilot production lines for automotive and new market applications.
The outlook remains high-risk with commercialization not expected until 2029, creating significant execution and competitive threats. While the consensus price target of $10.35 suggests potential upside from current levels, analyst sentiment is cautious with 73% hold ratings. Investment opportunity exists only for speculative investors comfortable with pre-revenue developmental stage risks and extended timelines to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →